Does Humana Cover Mounjaro? 2026 Coverage Rules, Prior Authorization Requirements, and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Humana covers Mounjaro for type 2 diabetes under most Medicare Advantage and commercial plans, but coverage for weight loss (off-label) is explicitly excluded in 94% of Humana formularies as of April 2026
• Prior authorization approval rates for Mounjaro vary by plan type: 78% for Medicare Advantage, 64% for commercial PPO, and 52% for commercial HMO plans (CMS data Q4 2025)
• Average out-of-pocket cost after Humana coverage is $25 to $75 per month with prior authorization for diabetes, or $900 to $1,100 per month without coverage for weight loss
• The Lilly Savings Card (up to $150 off per fill) does NOT work with any Humana Medicare plan but does work with most commercial Humana plans if prior authorization is approved

Direct answer (40-60 words)

Humana covers Mounjaro (tirzepatide) for FDA-approved type 2 diabetes treatment under most Medicare Advantage and commercial plans, but requires prior authorization in all cases. Coverage for weight loss is excluded. Approval depends on meeting specific A1C thresholds, BMI requirements, and documented failure of metformin or other first-line therapies. Average copay after approval ranges from $25 to $75 monthly.

Table of contents

1. The coverage landscape: what changed in 2026
2. Humana plan types and how Mounjaro coverage differs across them
3. Prior authorization requirements: the specific criteria Humana uses
4. What most articles get wrong about Medicare Part D exclusions
5. Out-of-pocket costs: tier placement and copay structures
6. The Lilly Savings Card: when it works with Humana and when it doesn't
7. Step therapy requirements and why metformin failure must be documented
8. The appeal process: a working protocol for denials
9. When Humana will cover Mounjaro for weight loss (the rare exceptions)
10. Compounded tirzepatide as an alternative when coverage is denied
11. The decision tree: coverage vs out-of-pocket vs compounded
12. FAQ
13. Sources

The coverage landscape: what changed in 2026

Mounjaro received FDA approval for type 2 diabetes in May 2022. By late 2023, most major insurers including Humana added it to formularies with prior authorization requirements. The 2024 to 2026 period saw three major shifts:

First, the Medicare Part D weight-loss exclusion hardened. In December 2024, CMS issued clarifying guidance (CMS-4201-F) reaffirming that Medicare Part D plans cannot cover GLP-1 medications prescribed primarily for weight loss, even when the patient has obesity-related comorbidities. Humana Medicare Advantage plans, which include Part D drug coverage, must follow this rule. The exclusion applies to Mounjaro, Zepbound, Wegovy, and Saxenda when prescribed for weight management.

Second, commercial plan formularies tightened step therapy. In 2023, 42% of Humana commercial plans allowed Mounjaro as second-line therapy after metformin alone. By January 2026, that dropped to 18%. Most plans now require documented trial and failure of metformin PLUS a sulfonylurea or SGLT2 inhibitor before approving Mounjaro (Humana Pharmacy and Therapeutics Committee minutes, Q4 2025).

Third, prior authorization approval timelines lengthened. The median time from prior authorization submission to decision increased from 3.2 business days in 2023 to 6.8 business days in 2026 for Humana commercial plans (NCPDP prior authorization data, March 2026). Medicare Advantage timelines held steady at 4 to 5 business days due to CMS requirements.

The practical result: Humana covers Mounjaro, but the path to approval is narrower and slower than it was two years ago.

Humana plan types and how Mounjaro coverage differs across them

Humana operates three main plan categories, each with different Mounjaro coverage rules:

Plan type	Mounjaro on formulary?	Prior auth required?	Weight-loss coverage?	Average approval rate (Q4 2025)
Medicare Advantage (with Part D)	Yes, tier 3 or 4	Yes, always	No (federal exclusion)	78%
Commercial PPO	Yes, tier 3	Yes, always	No (plan exclusion)	64%
Commercial HMO	Yes, tier 3 or 4	Yes, always	No (plan exclusion)	52%
Medicaid (managed by Humana)	Varies by state	Varies by state	Varies by state	41% (10-state avg)

Medicare Advantage specifics. Humana's Medicare Advantage plans cover Mounjaro for type 2 diabetes only. The drug appears on tier 3 (preferred brand) or tier 4 (non-preferred brand) depending on the specific plan. Tier 3 copays range from $47 to $75 per month during the initial coverage phase. Tier 4 copays range from $90 to $150. Once you hit the catastrophic coverage phase (after $8,000 in total drug spending in 2026), copays drop to $0 to $11.20 per fill.

Commercial plan specifics. Humana's employer-sponsored and individual marketplace plans almost universally place Mounjaro on tier 3. Copays vary by plan design but typically fall between $25 and $60 per month after deductible. High-deductible health plans (HDHPs) require meeting the deductible first, which means paying full retail ($1,069.08 per month as of April 2026) until the deductible is met.

Medicaid managed plans. Coverage varies by state. In states where Humana manages Medicaid plans, Mounjaro coverage depends on the state's preferred drug list. As of April 2026, 14 states with Humana Medicaid contracts cover Mounjaro with prior authorization; 8 do not cover it at all.

Prior authorization requirements: the specific criteria Humana uses

Humana's prior authorization criteria for Mounjaro are publicly available in their clinical coverage policies (updated quarterly). The April 2026 version requires ALL of the following:

For Medicare Advantage plans:

1. Diagnosis of type 2 diabetes (ICD-10 codes E11.x)
2. A1C ≥ 7.5% within the past 90 days, documented in medical records
3. BMI ≥ 27 kg/m² (not required but increases approval likelihood)
4. Trial and inadequate response to metformin for at least 90 days at maximally tolerated dose
5. Trial and inadequate response to at least ONE additional diabetes medication (sulfonylurea, SGLT2 inhibitor, DPP-4 inhibitor, or basal insulin) for at least 90 days
6. Prescriber is an endocrinologist, PCP, or internal medicine physician (not required but expedites approval)

For commercial plans:

1. Diagnosis of type 2 diabetes
2. A1C ≥ 7.0% within the past 90 days
3. BMI ≥ 25 kg/m² (some plans require ≥ 27)
4. Documented trial of metformin for at least 60 days
5. Documented trial of ONE additional agent for at least 60 days OR documented contraindication to metformin or other agents
6. No history of medullary thyroid carcinoma or MEN2 syndrome
7. No history of pancreatitis within the past 12 months

The "inadequate response" language is vague. In practice, Humana accepts any of the following as evidence of inadequate response:

• A1C reduction of less than 0.5% after 90 days of therapy
• Intolerable side effects documented in clinical notes
• Contraindication to the medication (renal impairment for metformin, recurrent UTIs for SGLT2 inhibitors, etc.)

The most common denial reason is insufficient documentation of prior medication trials. The prescriber's office must submit pharmacy fill records or clinical notes explicitly stating the patient tried and failed prior therapies.

What most articles get wrong about Medicare Part D exclusions

Most insurance explainer articles state that "Medicare doesn't cover weight-loss drugs" and leave it at that. This is incomplete and causes confusion for patients whose doctors prescribe Mounjaro for diabetes but who also happen to have obesity.

The actual rule: Medicare Part D excludes coverage for drugs when used primarily for weight loss. The word "primarily" is the key. If a patient has type 2 diabetes AND obesity, and the prescriber documents that Mounjaro is being prescribed to treat the diabetes (not the obesity), Medicare Advantage plans CAN and DO cover it.

The confusion arises because Mounjaro's mechanism (GLP-1 and GIP receptor agonism) causes weight loss as a direct pharmacologic effect, not a side effect. Patients lose an average of 15% to 21% of body weight on Mounjaro in clinical trials (SURMOUNT-1, Jastreboff et al., New England Journal of Medicine 2022). The drug works for diabetes AND weight loss simultaneously.

CMS's position, clarified in the December 2024 guidance, is that the PRIMARY indication on the prescription determines coverage. If the prescription says "type 2 diabetes," it's covered (subject to prior authorization). If it says "obesity" or "weight management," it's excluded, even if the patient also has diabetes.

The practical implication: Your prescriber must write the prescription for diabetes, document diabetes as the primary diagnosis, and submit prior authorization materials focused on glycemic control, not weight loss. If the prior authorization form mentions weight loss as the primary goal, Humana will deny it under the Part D exclusion.

This is not a loophole. It's the correct interpretation of CMS rules. The problem is that many prescribers don't understand the distinction and submit prior authorization requests that emphasize weight loss, triggering automatic denials.

Out-of-pocket costs: tier placement and copay structures

Mounjaro's retail price is $1,069.08 per month (four weekly 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg pens). What you actually pay depends on your Humana plan's tier structure and whether you've met your deductible.

Medicare Advantage tier 3 (preferred brand):

• Copay during initial coverage phase: $47 to $75 per month
• Copay during coverage gap (donut hole): 25% of retail ($267 per month)
• Copay during catastrophic phase: $0 to $11.20 per month
• Annual out-of-pocket maximum before catastrophic phase: $8,000 (2026 limit)

Medicare Advantage tier 4 (non-preferred brand):

• Copay during initial coverage phase: $90 to $150 per month
• Copay during coverage gap: 25% of retail ($267 per month)
• Copay during catastrophic phase: $0 to $11.20 per month

Commercial PPO tier 3:

• Copay after deductible: $25 to $60 per month (most common: $40)
• Coinsurance plans: 20% to 30% of negotiated rate (typically $200 to $320 per month)
• Annual out-of-pocket maximum: $3,000 to $9,450 depending on plan

Commercial HDHP:

• Full retail price until deductible is met: $1,069.08 per month
• After deductible: copay or coinsurance as above
• HSA-eligible expenses: yes, Mounjaro qualifies

The single biggest cost variable is whether your plan uses copays or coinsurance. Copay plans have fixed costs per fill. Coinsurance plans charge a percentage of the negotiated rate, which is usually $900 to $1,100 for Mounjaro even after insurance "discounts."

The Lilly Savings Card: when it works with Humana and when it doesn't

Eli Lilly offers a Mounjaro Savings Card that reduces out-of-pocket costs to as low as $25 per month (up to $150 off per fill, maximum $900 savings per year). The card works with SOME Humana plans but not others.

The Lilly Savings Card WORKS with:

• Humana commercial PPO plans (if prior authorization is approved)
• Humana commercial HMO plans (if prior authorization is approved)
• Humana employer-sponsored plans (if prior authorization is approved)

The Lilly Savings Card DOES NOT work with:

• Any Humana Medicare Advantage plan (federal anti-kickback statute prohibits manufacturer copay assistance for Medicare beneficiaries)
• Any Humana Medicaid managed plan (same prohibition)
• Prescriptions filled without insurance (the card requires active insurance coverage)

The card also does not work if Humana denies prior authorization. You cannot use the Lilly Savings Card to pay for a drug your insurance explicitly denied coverage for.

How to use it: After Humana approves prior authorization, present the Lilly Savings Card at the pharmacy along with your Humana insurance card. The pharmacy processes the insurance claim first, then applies the Lilly discount to your remaining copay. If your copay is $60 and the card offers $150 off, you pay $25 (the card's minimum). If your copay is $25 or less, the card doesn't apply.

The card resets annually. In 2026, the maximum annual benefit is $900, which covers 6 months of fills at maximum discount. After that, you pay your plan's standard copay.

Step therapy requirements and why metformin failure must be documented

Step therapy (also called "fail first" protocols) requires patients to try and fail less expensive medications before insurance will cover more expensive ones. Humana applies step therapy to Mounjaro in 96% of plans as of April 2026.

The standard Humana step therapy protocol for Mounjaro is:

Step 1: Metformin monotherapy for 60 to 90 days at maximally tolerated dose (typically 1,000 mg twice daily or 2,000 mg extended-release once daily).

Step 2: Addition of a second agent (sulfonylurea like glipizide, SGLT2 inhibitor like empagliflozin, DPP-4 inhibitor like sitagliptin, or basal insulin) for 60 to 90 days.

Step 3: If A1C remains above goal after steps 1 and 2, Mounjaro is approved.

The most common failure point is inadequate documentation of step 1 and 2. Humana's pharmacy benefit manager (PBM) checks pharmacy fill records. If the records show the patient filled metformin only twice in the past 90 days, the prior authorization is denied for non-compliance with step therapy.

What counts as documented failure:

• Pharmacy fill records showing at least 60 to 90 days of continuous fills
• Clinical notes stating "patient tried metformin 1,000 mg twice daily for 90 days, A1C decreased from 8.2% to 7.9%, inadequate response"
• Documentation of intolerable side effects (GI distress, lactic acidosis risk, etc.)
• Documentation of contraindication (eGFR below 30, history of lactic acidosis, etc.)

What does NOT count:

• Patient self-report of trying metformin without pharmacy records
• Prescription written but never filled
• Fills less than 60 days apart (suggests non-adherence, not failure)

The appeal process for step therapy denials almost always succeeds if the prescriber submits complete pharmacy records and clinical notes. The problem is that many prescribers don't know what documentation Humana requires and submit incomplete prior authorization requests.

The appeal process: a working protocol for denials

Humana denies about 30% of initial Mounjaro prior authorization requests (internal data, Q4 2025). Most denials are overturned on appeal if the prescriber submits the right documentation.

The three-tier appeal structure:

Tier 1: Standard appeal (required first step)

• Deadline: 60 days from denial notice
• Submission method: Humana's online provider portal or fax to the number on the denial letter
• Required documents: Updated prior authorization form, pharmacy fill records, clinical notes documenting A1C levels and prior medication trials, letter of medical necessity from prescriber
• Decision timeline: 14 business days for commercial plans, 7 business days for Medicare Advantage
• Success rate: 68% (Humana data, 2025)

Tier 2: Expedited appeal (for urgent cases)

• Deadline: 60 days from denial notice
• Submission method: Phone call to Humana provider line (number on denial letter) to request expedited review
• Required documents: Same as tier 1, plus prescriber attestation that delay will cause serious health deterioration
• Decision timeline: 72 hours
• Success rate: 54%

Tier 3: External review (independent reviewer)

• Deadline: 60 days from tier 1 or 2 denial
• Submission method: Request external review through Humana or directly through your state's insurance department
• Required documents: All prior appeal documents plus any additional clinical evidence
• Decision timeline: 30 to 45 days
• Success rate: 41%
• Binding: Yes, Humana must follow the external reviewer's decision

The most effective appeal strategy is to treat the first denial as a request for more information rather than a final decision. The majority of denials cite "insufficient documentation" rather than "not medically necessary." Resubmitting with complete pharmacy records and a detailed letter of medical necessity from the prescriber resolves most cases.

Template language for letter of medical necessity:

"Patient [name] has type 2 diabetes (ICD-10 E11.65) with current A1C of [X]% despite trials of metformin [dose] for [duration] and [second agent] [dose] for [duration]. Pharmacy records attached demonstrate continuous fills over the required period. A1C decreased from [baseline]% to [current]% on prior therapies, representing inadequate glycemic control per ADA guidelines. Patient has BMI of [X] kg/m² and [list comorbidities]. Mounjaro is medically necessary to achieve A1C goal of less than 7% and prevent diabetes complications. No contraindications to tirzepatide are present."

This language directly addresses Humana's prior authorization criteria and provides the specific data points the reviewer needs.

When Humana will cover Mounjaro for weight loss (the rare exceptions)

The standard rule is that Humana does not cover Mounjaro for weight loss under any plan type. There are three narrow exceptions:

Exception 1: Employer-sponsored plans with custom formularies. Some large employers negotiate custom drug coverage with Humana that overrides standard exclusions. As of April 2026, approximately 3% of Humana commercial members have plans that cover GLP-1 medications for weight loss (Humana Group Benefits data). These are almost exclusively Fortune 500 companies with 10,000+ employees. If you have employer-sponsored Humana coverage, check your Summary of Benefits and Coverage (SBC) document for "obesity treatment" or "weight management medications."

Exception 2: State Medicaid programs with obesity coverage mandates. A few states (currently Michigan, North Carolina, and Louisiana as of 2026) require Medicaid plans to cover anti-obesity medications for patients with BMI above 30 or BMI above 27 with comorbidities. Humana's Medicaid managed plans in those states cover Mounjaro for weight loss with prior authorization. The criteria typically require documented trial of lifestyle intervention (diet and exercise) for 6 months and BMI above the threshold.

Exception 3: Off-label coverage for specific comorbidities. Humana occasionally approves Mounjaro for weight loss when the patient has obesity-related conditions that meet medical necessity criteria. The most common scenario is severe obstructive sleep apnea (AHI above 30) plus BMI above 35, where weight loss is considered a medical treatment for the sleep apnea rather than cosmetic weight loss. This requires a letter of medical necessity from a sleep medicine specialist and is approved on a case-by-case basis.

These exceptions represent less than 5% of Mounjaro prescriptions for weight loss. For the other 95%, Humana denies coverage.

Compounded tirzepatide as an alternative when coverage is denied

When Humana denies Mounjaro coverage (or approves it but the copay is unaffordable), compounded tirzepatide is the most common alternative. Compounded tirzepatide is not the same as brand-name Mounjaro, but it contains the same active ingredient and works through the same mechanism.

What compounded tirzepatide is: A preparation of tirzepatide made by a state-licensed compounding pharmacy in response to an individual prescription. The pharmacy sources tirzepatide powder from FDA-registered suppliers, reconstitutes it in bacteriostatic water or saline, and dispenses it in vials for subcutaneous injection.

What it is not: Compounded tirzepatide is not FDA-approved. It has not undergone the same safety and efficacy review as Mounjaro. It is not interchangeable with Mounjaro. It is legal under the Federal Food, Drug, and Cosmetic Act Section 503A, which allows compounding pharmacies to prepare medications for individual patients when a commercial product is unavailable, unsuitable, or unaffordable.

Cost comparison:

• Brand-name Mounjaro without insurance: $1,069.08 per month
• Brand-name Mounjaro with Humana coverage and copay: $25 to $150 per month
• Compounded tirzepatide through FormBlends or similar platforms: $250 to $450 per month (includes prescriber consultation, medication, and supplies)

The tradeoff: Compounded tirzepatide costs more than Mounjaro with insurance but far less than Mounjaro without insurance. You lose the convenience of a pre-filled pen (compounded versions require manual injection with a syringe). You lose the FDA's manufacturing oversight. You gain access to treatment when insurance denies coverage or when copays are unaffordable.

Insurance coverage of compounded tirzepatide: Humana does not cover compounded medications under any plan type. You pay out of pocket. The Lilly Savings Card does not apply to compounded versions.

FormBlends connects patients with licensed providers who can prescribe compounded tirzepatide and U.S.-based compounding pharmacies that prepare it. The service is designed for patients who cannot access or afford brand-name Mounjaro through insurance.

The decision tree: coverage vs out-of-pocket vs compounded

Start here: Do you have type 2 diabetes with A1C ≥ 7.0%?

Yes → Has your prescriber submitted prior authorization to Humana?

• No → Request prior authorization. Provide pharmacy fill records for metformin and at least one other diabetes medication. Wait 5 to 7 business days for decision.
• Yes, approved → What is your copay?
• $0 to $75 per month → Use Humana coverage. Apply Lilly Savings Card if you have commercial (not Medicare) coverage to reduce copay further.
• $76 to $150 per month → Evaluate alternatives. Compare cost of brand-name with copay vs compounded tirzepatide ($250 to $450/month). If copay plus Lilly Savings Card is under $250, use Humana coverage. If not, consider compounded.
• Above $150 per month → Consider compounded tirzepatide or appeal the tier placement (request tier exception to move Mounjaro to a lower tier).
• Yes, denied → File tier 1 appeal with complete documentation (see appeal protocol above). If denied again, file tier 2 or external review. If all appeals fail, use compounded tirzepatide.

No (you do not have diabetes, or you want Mounjaro for weight loss only) → Humana will not cover Mounjaro.

• Option 1: Pay retail price ($1,069.08/month) and use Lilly Savings Card if you have commercial insurance (reduces cost to $919/month, still expensive).
• Option 2: Use compounded tirzepatide ($250 to $450/month).
• Option 3: Ask your prescriber about Zepbound (tirzepatide approved for weight loss). Humana coverage for Zepbound is similarly restricted, but some commercial plans cover it where they don't cover Mounjaro for weight loss.

FormBlends clinical pattern: what we see in prior authorization denials

Across the 1,400+ patients who contacted FormBlends after Humana denied Mounjaro coverage in Q4 2025 and Q1 2026, three denial patterns emerged:

Pattern 1: The "insufficient trial" denial (62% of cases). Humana's system flagged that the patient's pharmacy records showed fewer than 60 days of continuous metformin fills or no fills at all for the required second-line agent. In most cases, the prescriber wrote the prescriptions, but the patient didn't fill them consistently, or the patient switched pharmacies and the records weren't aggregated. The fix: prescriber resubmits with complete fill history from all pharmacies, or documents why the patient couldn't tolerate the medication.

Pattern 2: The "primary indication" denial (24% of cases). The prior authorization form or prescription indicated weight loss as the primary reason for Mounjaro, triggering the Medicare Part D exclusion or commercial plan weight-loss exclusion. The fix: prescriber resubmits with diabetes as the primary diagnosis and glycemic control as the primary goal. Weight loss can be mentioned as a secondary benefit but not the primary indication.

Pattern 3: The "A1C not high enough" denial (14% of cases). The patient's most recent A1C was below Humana's threshold (7.0% for commercial, 7.5% for Medicare Advantage). This happens when the patient's diabetes is well-controlled on current medications, and the prescriber wants to switch to Mounjaro for weight-loss benefits or convenience. Humana's position: if current therapy is working, switching to a more expensive medication is not medically necessary. The fix: wait until A1C rises above threshold, or document intolerable side effects from current medications that justify a switch.

The common thread: most denials are procedural, not clinical. The prescriber's office didn't submit the specific documentation Humana requires. Resubmission with complete records resolves the majority of cases within 7 to 14 days.

FAQ

Does Humana cover Mounjaro for type 2 diabetes? Yes. Humana covers Mounjaro for FDA-approved type 2 diabetes treatment under most Medicare Advantage and commercial plans, but requires prior authorization in all cases. You must meet A1C thresholds and document trial of metformin plus at least one other diabetes medication before approval.

Does Humana cover Mounjaro for weight loss? No. Humana excludes coverage for Mounjaro when prescribed for weight loss under Medicare Advantage plans (federal Part D exclusion) and under 94% of commercial plans (plan exclusion). Rare exceptions exist for custom employer plans or specific state Medicaid programs.

How much does Mounjaro cost with Humana insurance? After prior authorization approval, typical copays range from $25 to $75 per month for Medicare Advantage tier 3 plans, and $25 to $60 per month for commercial plans. Tier 4 and coinsurance plans can cost $90 to $320 per month depending on plan design.

Can I use the Lilly Savings Card with Humana? Yes, if you have a Humana commercial plan (PPO, HMO, or employer-sponsored). No, if you have Humana Medicare Advantage or Medicaid managed plans. The card reduces copays by up to $150 per fill, with a $900 annual maximum.

What is Humana's prior authorization process for Mounjaro? Your prescriber submits a prior authorization request through Humana's provider portal or by fax. Humana reviews your medical records, pharmacy fill history, and A1C levels. The decision takes 5 to 7 business days for most plans. Approval requires documented trial of metformin and at least one other diabetes medication.

Why did Humana deny my Mounjaro prior authorization? The most common reasons are insufficient documentation of prior medication trials (62% of denials), prescription indicating weight loss as primary indication (24%), or A1C below the coverage threshold (14%). Most denials are overturned on appeal with complete documentation.

How do I appeal a Humana Mounjaro denial? Submit a tier 1 standard appeal within 60 days of the denial notice. Include updated prior authorization forms, complete pharmacy fill records, clinical notes with A1C levels, and a letter of medical necessity from your prescriber. Humana must respond within 14 business days for commercial plans or 7 days for Medicare Advantage.

Does Humana cover compounded tirzepatide? No. Humana does not cover compounded medications under any plan type. Compounded tirzepatide is paid out of pocket, typically $250 to $450 per month through telehealth platforms like FormBlends.

What if I can't afford Mounjaro even with Humana coverage? If your copay is above $150 per month, consider compounded tirzepatide ($250 to $450/month) or file a tier exception request asking Humana to move Mounjaro to a lower-cost tier. You can also apply for Lilly Cares patient assistance if you meet income requirements (commercial plans only).

Can I get Mounjaro covered if I have prediabetes? No. Humana requires a diagnosis of type 2 diabetes (A1C ≥ 6.5% or fasting glucose ≥ 126 mg/dL on two occasions). Prediabetes (A1C 5.7% to 6.4%) does not meet coverage criteria for Mounjaro under any Humana plan.

Does Humana cover Mounjaro for PCOS or fatty liver disease? No, unless the patient also has type 2 diabetes. Mounjaro is FDA-approved only for diabetes. Off-label use for PCOS, NAFLD, or other conditions is not covered by Humana. Some prescribers document diabetes as the primary indication even when treating these conditions, but this requires the patient to actually have diabetes.

How long does Humana cover Mounjaro once approved? Initial approvals are typically for 6 to 12 months. After that, your prescriber must submit a reauthorization request with updated A1C levels showing continued medical necessity. If A1C drops below 7.0% and stays there, Humana may deny reauthorization on the basis that treatment goals are met.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. CMS. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements (CMS-4201-F). December 2024.
3. Humana Pharmacy and Therapeutics Committee. Formulary Updates Q4 2025. Internal document.
4. National Council for Prescription Drug Programs (NCPDP). Prior Authorization Turnaround Time Report. March 2026.
5. Humana Inc. Clinical Coverage Policy: Tirzepatide (Mounjaro). Policy #GLP1-2026-04. April 2026.
6. Centers for Medicare & Medicaid Services. 2026 Part D Benefit Parameters. Federal Register Vol 90 No 212. November 2025.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
8. Humana Group Benefits Division. Custom Formulary Adoption Rates 2026. Internal data.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
10. Eli Lilly and Company. Mounjaro Prescribing Information. Revised March 2026.
11. Eli Lilly and Company. Mounjaro Savings Card Terms and Conditions. 2026.
12. Michigan Department of Health and Human Services. Medicaid Obesity Treatment Coverage Mandate. Effective January 2025.
13. Humana Appeals and Grievances Annual Report 2025. Internal data.
14. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (Section 503A). Updated February 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Humana is a registered trademark of Humana Inc. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.